Article

3 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 62, n° 3
pages 387-392 (mars 2010)
Doi : 10.1016/j.jaad.2009.08.054
accepted : 14 August 2009
Original Articles

Hydroxychloroquine and lichen planopilaris: Efficacy and introduction of Lichen Planopilaris Activity Index scoring system
 

Charles Chiang, MD a, Deborah Sah, MD b, Bryan K. Cho, MD c, Blanca E. Ochoa d, Vera H. Price, MD a,
a Department of Dermatology at University of California, San Francisco, California 
b Palo Alto Medical Foundation, Fremont Center, Fremont, California 
c Department of Dermatology at Palo Alto Medical Foundation, Camino Medical Group, Mountain View, California 
d Department of Dermatology at Baylor College of Medicine, Houston, Texas 

Reprint requests: Vera H. Price, MD, Department of Dermatology at University of California, San Francisco, 1701 Divisadero St, Third Floor, San Francisco, CA 94143.
Abstract
Background

Lichen planopilaris (LPP) and its variant frontal fibrosing alopecia (FFA) are primary lymphocytic cicatricial alopecias for which there is no evidence-based therapy.

Objective

We assessed the efficacy of hydroxychloroquine in active LPP and FFA using the LPP Activity Index (LPPAI), a numeric score that allows quantification of the symptoms and signs of the condition for statistical comparison. In addition, we determined with the LPPAI if any improvement (reduction) in the numeric score pretreatment and posttreatment reached statistical significance.

Methods

This was a retrospective, single-center chart review of 40 adult patients with LPP, FFA, or both who were treated with hydroxychloroquine for up to 12 months from 2004 to 2007 at the University of California, San Francisco Hair Center. Symptoms, signs, activity, and spreading were scored at each visit in the standardized cicatricial alopecia flow chart. A numeric score was assigned to these markers of disease activity and a numeric score was calculated at each visit.

Results

There was significant reduction (P < .001) in the LPPAI at both 6 and 12 months. After 6 months, 69% had improved (reduced) symptoms and signs. At 12 months, 83% had improvement (reduction) in symptoms and signs.

Limitations

Retrospective analysis and uncontrolled study are limitations.

Conclusions

Hydroxychloroquine is effective in decreasing symptoms and signs in LPP and FFA as shown by significant reduction in the LPPAI in 69% and 83% of patients after 6 and 12 months of treatment, respectively.

The full text of this article is available in PDF format.

Key words : cicatricial alopecia, frontal fibrosing alopecia, hydroxychloroquine, lichen planopilaris, Lichen Planopilaris Activity Index

Abbreviations used : FFA, LPP, LPPAI, UCSF



 Funding sources: None.
 Conflicts of interest: None declared.



© 2009  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline